Cargando…

Corrigendum: Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes

Detalles Bibliográficos
Autor principal:	Deacon, Carolyn F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511808/ https://www.ncbi.nlm.nih.gov/pubmed/31133983 http://dx.doi.org/10.3389/fendo.2019.00275

Ejemplares similares

Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
por: Deacon, Carolyn F.
Publicado: (2019)

Impact of dipeptidyl peptidase-4 inhibitors on glucose-dependent insulinotropic polypeptide in type 2 diabetes mellitus: a systematic review and meta-analysis
por: Chai, Shangyu, et al.
Publicado: (2023)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
por: Gilbert, Matthew P., et al.
Publicado: (2020)

Increased Plasma Dipeptidyl Peptidase-4 (DPP4) Activity Is an Obesity-Independent Parameter for Glycemic Deregulation in Type 2 Diabetes Patients
por: Sarkar, Jit, et al.
Publicado: (2019)

DPP-4 Inhibition and the Path to Clinical Proof
por: Ahrén, Bo
Publicado: (2019)

Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis
por: Liao, Xiaoyu, et al.
Publicado: (2019)

GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
por: Brunton, S
Publicado: (2014)

Efficacy of combination therapy with GABA, a DPP-4i and a PPI as an adjunct to insulin therapy in patients with type 1 diabetes
por: Rabinovitch, Alexander, et al.
Publicado: (2023)

Pancreas-derived DPP4 is not essential for glucose homeostasis under metabolic stress
por: Fadzeyeva, Evgenia, et al.
Publicado: (2023)

The Physiological Role of Ghrelin in the Regulation of Energy and Glucose Homeostasis
por: Sovetkina, Alina, et al.
Publicado: (2020)

Corrigendum: Insulin Action, Glucose Homeostasis and Free Fatty Acid Metabolism: Insights From a Novel Model
por: Stefanovski, Darko, et al.
Publicado: (2021)

Maternal Chronodisruption Throughout Pregnancy Impairs Glucose Homeostasis and Adipose Tissue Physiology in the Male Rat Offspring
por: Halabi, Diego, et al.
Publicado: (2021)

Astrocyte Clocks and Glucose Homeostasis
por: Barca-Mayo, Olga, et al.
Publicado: (2021)

Editorial: Epigenetics of Glucose Homeostasis
por: Georgia, Senta, et al.
Publicado: (2022)

A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity
por: Chhabria, Srishti, et al.
Publicado: (2022)

Editorial: Understanding the role of gut hormones, microbiota, and miRNAs in metabolic regulation and glucose homeostasis in obesity and type-2-diabetes
por: Matz, Lisa M., et al.
Publicado: (2023)

Endogenous GLP-1 levels play an important role in determining the efficacy of DPP-IV Inhibitors in both prediabetes and type 2 diabetes
por: Chong, Shiau Chin, et al.
Publicado: (2022)

SUN-062 Randomized Controlled Trial for Assessment of the Effects of Anaglipitin, a DPP-4 Inhibitor, on Blood Lipids in Type 2 Diabetic Patients
por: Onoue, Takeshi, et al.
Publicado: (2019)

Pharmacological approaches to the prevention of type 2 diabetes mellitus
por: Majety, Priyanka, et al.
Publicado: (2023)

Neurotensin and its receptors in the control of glucose homeostasis
por: Mazella, Jean, et al.
Publicado: (2012)

The serum concentration and activity of DPP4 is positively related with the severity of hyperthyroidism in patients with Graves’ disease
por: Chang, Xiaona, et al.
Publicado: (2023)

Effectiveness and safety of glimepiride and iDPP4, associated with metformin in second line pharmacotherapy of type 2 diabetes mellitus: systematic review and meta‐analysis
por: Amate, JM., et al.
Publicado: (2015)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

Is Endogenous GLP-1 the Only Important Enhancer of Glucose-Induced Insulin Secretion in Type 2 Diabetes?
por: Deacon, Carolyn F.
Publicado: (2012)

DPP4 in Diabetes
por: Röhrborn, Diana, et al.
Publicado: (2015)

Ion channels in the central regulation of energy and glucose homeostasis
por: Sohn, Jong-Woo
Publicado: (2013)

Impact of Nutrient Type and Sequence on Glucose Tolerance: Physiological Insights and Therapeutic Implications
por: Nesti, Lorenzo, et al.
Publicado: (2019)

Intestinal Barrier Function and Immune Homeostasis Are Missing Links in Obesity and Type 2 Diabetes Development
por: Riedel, Sylvia, et al.
Publicado: (2022)

Combining bioinformatics, network pharmacology and artificial intelligence to predict the mechanism of celastrol in the treatment of type 2 diabetes
por: Wu, Ming, et al.
Publicado: (2022)

Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case–control study
por: Giorda, Carlo B, et al.
Publicado: (2015)

Potential of liraglutide in the treatment of patients with type 2 diabetes
por: Deacon, Carolyn F
Publicado: (2009)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
por: Stenlid, Rasmus, et al.
Publicado: (2023)

Oral formulation of DPP-4 inhibitor plus Quercetin improves metabolic homeostasis in type 1 diabetic rats
por: Miranda, Pedro Henrique de A., et al.
Publicado: (2018)

Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
por: Ahrén, Bo
Publicado: (2008)

Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes
por: Vitale, Cristiana, et al.
Publicado: (2016)

Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study
por: Sanada, Junpei, et al.
Publicado: (2021)

Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
por: Yang, Yinqiu, et al.
Publicado: (2020)

A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
por: Jeong, Su Hyun, et al.
Publicado: (2023)

Hypothalamic Proopiomelanocortin Is Necessary for Normal Glucose Homeostasis in Female Mice
por: Alsina, Ramiro, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_11fsgn1q1vfkiv22jdeopri4s9